Epidemiology of Pneumocystis carinii pneumonia in an era of effective prophylaxis: The relative contribution of non-adherence and drug failure

AIDS

Volumn 14, Issue 16, 2000, Pages 2559-2566

  Lundberg, Brita E ^a,b   Davidson, Arthur J ^a,b   Burman, William J ^a,b,c  

^a DENVER HEALTH AND HOSPITAL AUTHORITY   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c DENVER PUBLIC HEALTH   (United States)

Author keywords

Adherence; Antiretroviral therapy; Compliance; Dapsone; Drug resistance; HIV infection; Pentamidine; Pneumocystis carinii pneumonia; Prophylaxis; Trimethoprim sulfamethoxazole

Indexed keywords

COTRIMOXAZOLE; DAPSONE; PENTAMIDINE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG USE; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PNEUMOCYSTIS PNEUMONIA; PRESCRIPTION; PRIORITY JOURNAL; RACE DIFFERENCE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TREATMENT FAILURE;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-INFECTIVE AGENTS; CASE-CONTROL STUDIES; CHEMOPREVENTION; FEMALE; HUMANS; MALE; MULTIVARIATE ANALYSIS; PNEUMONIA, PNEUMOCYSTIS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT FAILURE; TREATMENT REFUSAL;

EID: 0033747054     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200011100-00019     Document Type: Article

References (37)

1. An outbreak of community-acquired Pneumocystis carinii pneumonia: Initial manifestation of cellular immune dysfunction
2. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS
3. A metaanalysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens
4. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome
5. Randomised trial of addition of lamivudine of lamivudine plus lovaride to zidovudine-containing regimens for patients with HIV-1 infection: The CAESAR trial
6. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
7. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
8. The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs
9. Pneumocystis carinii pneumonia (PCP) in the era of chemoprophylaxis
10. Pneumocystis carinii pneumonia in the protease inhibitor era
11. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection
12. Dihydropteroate synthase polymorphisms in Pneumocystis carinii
13. Failure of cotrimoxazole in Pneumocystis carinii infection and mutations in dihydropteroate synthase gene
14. Adherence to guidelines for the prevention of HIV-related respiratory diseases
15. The continued occurrence of primary Pneumocystis carinii pneumonia despite the availability of prophylaxis
16. The impact of prophylaxis on outcome and resource utilization in Pneumocystis carinii pneumonia
17. Spectrum of disease in persons with human immunodeficiency virus infection in the United States
18. USPHS: Disease-specific recommendations: Pneumocystis carinii pneumonia
19. Trimetrexante with leukovorin versus trimethoprim-sulfamethoxasole for moderate to severe episodes of Pneumocystis carinii pneumonia in patients with AIDS: A prospective, controlled multicenter investigation of the AIDS clinical trials group protocol 029/031
20. A controlled study of inhaled pentamidine for primary prevention of Pneumocystis carinii pneumonia
21. Randomized trial of dapsone and aerosolized pentamidine for the prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis
22. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both
23. Cost of care for patients with HIV infection: Pattern of utilization and charges in a public health care system
24. Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus
25. Validation of pharmacy records in drug exposure assessment
26. Sustained improvement in drug documentation, compliance, and disease control
27. A general method of compliance assessment using centralized pharmacy records: Description and validation
28. MEMS devices to measure adherence among HIV infected patients
29. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1 infected adults treated with combination antiretroviral therapy
30. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy
31. 1999 USPHS/IDSA guidelines for the prophylaxis of opportunistic infections in persons infected with human immunodeficiency virus: U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA)
32. ACTG 268 Trial - Gradual initiation of trimethoprim/sulfamethoxazole (T/S) as primary prophylaxis for Pneumocystis carinii pneumonia
33. A randomized, double-blind trial of TMP/SMX dose escalation vs. direct rechallenge in HIV+ persons at risk for PCP and with prior treatment-limiting rash or fever
34. Indinavir compliance in a large urban HIV clinic
35. A critical review of the determinants of patient compliance
36. Diagnosing potential noncompliance: Physicians' ability in a behavioral dimension of medical care
37. Manipulation of therapeutic regimen to improve compliance: Conceptions and misconceptions